Sumati V. Gupta
Professor
Department of Oncological Sciences
Huntsman Cancer Institute
United States of America
Biography
Sumati Gupta, MD, is an Assistant Professor in the Division of Oncology, Department of Medicine, at University of Utah‘s Huntsman Cancer Institute. Dr. Gupta is a specialist in adult medical oncology and her main areas of interest include Genitourinary Cancer (bladder, kidney, prostate and testicular cancer). Dr. Gupta earned her medical degree from University of Mumbai (KEM) in India. She then completed a residency in Internal Medicine at SUNY Stony Brook, East Meadow program at Nassau University Medical Center. Dr. Gupta then completed a fellowship in Geriatrics at Baylor College of Medicine in Houston, Texas. She practiced at the University of Utah Clinics for 10 years in Primary Care and Geriatrics. Dr. Gupta then completed fellowship in Medical Oncology at the University of Utah and the Huntsman Cancer Institute. She is board certified in Internal Medicine and Medical Oncology.
Research Interest
Mechanisms of Chemotherapy Resistance Immunotherapy
Publications
-
Gupta S, Agarwal A (2002). Hypoxia after Upper Gastro-esophageal Endoscopy. Patient Care, 36(3), 49.
-
Gupta S (2002). Retrospective study on the effect of chronic ACE inhibitor therapy on inter-dialysis weight gain in patients on hemodialysis. Ren Fail, Jul;24(4), 461-6.
-
Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
-
Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma S (2016). Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP [Epub ahead of print]. Invest New Drugs, 2016(Feb 20).
-
Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma S (2016). Reversible Lysine-Specific Demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-myc in castration-resistant and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis.
-
Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.LID - S1558-7673(16)30354-8 [pii]LID - 10.1016/j.clgc.2016.12.008 [doi]. (Epub ahead of print) Clin Genitourin Cancer.
